Multiple Sclerosis (MS) – Demyelinating Disorder; It’s Overview, Indications, Etiology, Pathophysiology and Clinical Pharmacotherapy

Abstract

Multiple sclerosis (MS) is also called as demyelinating disorder in which myelin sheath of neurons affected which ultimately affects the cognitive impairment and cause mobility disorders. Worldwide the Multiple sclerosis influences 2.5 million citizens plus 400,000 Americans. The main cause is still unknown but the researchers find that due to genetic, immunologic and environmental factors, myelin sheath could be damage. The treatment protocol depends upon the severity and the symptoms of the disease. Certain medications like Natalizumab, Dimethyl fumarate etc is used to treat relapses in MS. In case of severe illnesses, the patient response is being discontinued then the doctor and pharmacist ought to prefer palliative care for the wellbeing of the patient. The main objective of this review study is to give a glance about the multiple features of this disease state, its morbidity and co-morbidity, types and proper management by appropriate medications in order to avoid any drug interaction and toxicity.